Recent Updates
Recently added Catalysts
CLLS Positive Sentiment

CELLECTIS Shareholders Meeting

Friday, December 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: During a shareholders meeting on December 22, 2023, CELLECTIS approved the creation of two new classes of preferred shares, Class A and Class B, with significant shareholder backing. The board was delegated authority to increase share capital by issuing these new shares, which reflects a proactive approach to capital management. Additionally, two new directors were appointed, suggesting an effort to strengthen leadership. However, a proposal for a company savings plan was not approved by shareholders, indicating some dissent in certain areas.
Price reaction · baseline $3.37 (2023-12-21 close) · hit after-hours · clean, no other CLLS news in the window
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of new Class A and Class B preferred shares.
  • Successful capital increases with extensive shareholder support.
  • Appointment of two new directors potentially enhances governance.

CONCERNS & RISKS

  • One resolution related to the company savings plan was rejected.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
4.6%
average across 4 past catalysts
Lead asset
UCART22
Phase 1 · B-cell Acute Lymphoblastic Leukemia

Full Press Release Details

CELLECTIS Shareholders Meeting December 22, 2023
Extraordinary Resolutions
NB Resolution Result For Against Vote withhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of vote voting rights Null voting rights Quorum
Votes % Votes % Votes %
1 Creation of a class of preferred shares referred to as Class A preferred shares convertible into ordinary shares (the A Shares ) - determination of the specific rights attached to the A Shares - corresponding amendment to the bylaws
1 Carried 26 188 875 99,65 % 92 063 0,35 % 35 416 26 280 938 21 466 266 29,917 % 0 0 29,917 %
2 Delegation of authority to the board of directors to increase the share capital by a maximum nominal amount of EUR 500,000, through the issuance of a maximum of 10,000,000 A Shares, with cancellation of the shareholders preferential subscription rights in favor of a named person
2 Carried 26 171 469 99,55 % 118 145 0,45 % 26 740 26 289 614 21 466 266 29,917 % 0 0 29,917 %
3 Creation of a class of preferred shares referred to as Class B preferred shares convertible into ordinary shares (the B Shares ) - determination of the specific rights attached to the B Shares - corresponding amendment to the bylaws
3 Carried 26 189 117 99,63 % 97 794 0,37 % 29 443 26 286 911 21 466 266 29,917 % 0 0 29,917 %
4 Delegation of authority to the board of directors to increase the share capital by a maximum nominal amount of EUR 900,000, through the issuance of a maximum of 18,000,000 B Shares, with cancellation of the shareholders preferential subscription rights in favor of a named person
4 Carried 26 198 396 99,63 % 96 411 0,37 % 21 547 26 294 807 21 466 266 29,917 % 0 0 29,917 %
5 Cancellation of the shareholders preferential subscription rights in favor of AstraZeneca Holdings B.V.
5 Carried 26 205 300 99,67 % 88 077 0,33 % 22 977 26 293 377 21 466 266 29,917 % 0 0 29,917 %
6 Delegation of authority to the board of directors to carry out a share capital increase reserved for members of a company savings plan set up in accordance with Articles L. 3332-1 et seq. of the French Labor Code
6 Rejected 6 297 651 23,95 % 19 998 142 76,05 % 20 561 26 295 793 21 466 266 29,917 % 0 0 29,917 %
CELLECTIS Shareholders Meeting December 22, 2023
Ordinary Resolutions
NB Resolution Result For Against Vote withhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of vote voting rights Null voting rights Quorum
Votes % Votes % Votes %
7 Appointment of a director (Mr. Marc Dunoyer) subject to condition precedent
7 Carried 25 945 461 98,65 % 354 396 1,35 % 16 497 26 299 857 21 466 266 29,917 % 0 0 29,917 %
8 Appointment of a director (Mr. Tyrell Rivers) subject to condition precedent
8 Carried 26 032 194 99,03 % 253 663 0,97 % 30 497 26 285 857 21 466 266 29,917 % 0 0 29,917 %

Frequently Asked Questions

What is the result of the creation of Class A shares?

The creation of Class A preferred shares was approved with 99.65% support.

How much can the board increase the share capital by?

The board can increase the share capital by a maximum of EUR 500,000.

What percentage approved the creation of Class B shares?

The creation of Class B preferred shares was approved with 99.63% support.

What was the outcome for the share capital increase for AstraZeneca?

The cancellation of shareholders' rights in favor of AstraZeneca was approved.

Were any resolutions rejected at the meeting?

Yes, the resolution for a share capital increase for a savings plan was rejected.

ShareAdd on Google
Tags: CLLS Viatris Investor Conferences Healthcare CELLECTIS shareholder meeting preferred shares AstraZeneca
Last updated: Dec 22, 2023

Biotech snapshot

Lead asset
UCART22Phase 1
B-cell Acute Lymphoblastic Leukemia →

Catalyst track record

+13%
best trade around CLLS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for CLLS.

See every catalyst's timing & PoA →